Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
Open Access
Abstract
Designing specific therapies for drug-resistant cancers is arguably the ultimate challenge in cancer therapy. While much emphasis has been put on the study of genetic alterations that give rise to drug resistance, much less is known about the non-genetic adaptation mechanisms that operate during the early stages of drug resistance development. Drug-tolerant persister cells have been suggested to be key players in this process. These cells are thought to have undergone non-genetic adaptations that enable survival in the presence of a drug, from which full-blown resistant cells may emerge. Such initial adaptations often involve engagement of stress response programs to maintain cancer cell viability. In this review, we discuss the nature of drug-tolerant cancer phenotypes, as well as the non-genetic adaptations involved. We also discuss how malignant cells employ homeostatic stress response pathways to mitigate the intrinsic costs of such adaptations. Lastly, we discuss which vulnerabilities are introduced by these adaptations and how these might be exploited therapeutically.Keywords
Funding Information
- ERC Advanced Grant (SENCAN, #787925)
This publication has 100 references indexed in Scilit:
- Synthetic lethal metabolic targeting of cellular senescence in cancer therapyNature, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cellsLeukemia, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem CellsScience Translational Medicine, 2010
- Principles of Cancer Therapy: Oncogene and Non-oncogene AddictionCell, 2009
- Activation of the DNA damage checkpoint and genomic instability in human precancerous lesionsNature, 2005
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005
- In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysisBlood, 2004